(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.
Justices heard arguments from federal officials Monday that these deals can be anticompetitive and keeps lower-cost generic drugs out of American hands. But pharmaceutical companies say these deals save litigation costs and often bring generics to market faster.
A government lawyer argued the companies should be forced to prove that their deals serve a purpose beyond simply paying a generic drug's maker not to challenge a brand-name drug's patent.
But a pharmaceutical company lawyer says they shouldn't be forced to litigate each generic vs. brand-name drug patent lawsuit to conclusion when a settlement can be reached.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
High court weighs drug companies' generics policy (2013, March 25)
retrieved 22 October 2019
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
Your feedback will go directly to Science X editors.
E-mail the story
High court weighs drug companies' generics policy